Navigation Links
Prix Galien USA Honors Innovation in Science and Biotech Industries
Date:10/1/2009

NEW YORK, Oct. 1 /PRNewswire-USNewswire/ -- The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition. Novartis Oncology, Amgen, GlaxoSmithKline and Veridex were honored with the 2009 Prix Galien USA, considered the industry's highest accolade for pharmaceutical research and development, for treatments that could change the course of health care worldwide.

"The 2009 Prix Galien USA winners represent what is possible when basic scientific research translates to drug development and discovery," said Gerald Weissmann, M.D., Prix Galien USA committee chair, NYU School of Medicine research professor of medicine, director of biotechnology study center, and editor-in-chief of The FASEB Journal. "We all benefit from the research that provides new treatments for the millions of cancer patients worldwide and for the patients living with rare blood diseases. Basic research translates into future knowledge and improved health for all of us."

At the gala awards ceremony, the committee presented Barry Bloom, Ph.D., Joan L. and Julius H. Jacobson professor of public health at the Harvard School of Public Health, and Jeffrey Sachs, Ph.D., director of The Earth Institute, Quetelet Professor of Sustainable Development, and professor of health policy and management at Columbia University, with the Pro Bono Humanum Award. Dr. Barry Bloom was honored for his work to support efforts to eradicate disease by understanding the immune responses to infectious diseases. Dr. Sachs was honored for the Millennium Villages, a project which has helped rural African communities and close to half a million people lift themselves out of extreme poverty by providing basic interventions that address needs in business development, food, health, infrastructure and education.

The Prix Galien 2009 winners, selected from 21 candidates, are:

Best Pharmaceutical Product:

  • Novartis Oncology, GLEEVEC(R) -- By targeting the specific cancer-causing molecules in the body, GLEEVEC(R)( )attacks cancerous cells while sparing healthy cells and the immune system.

Best Biotechnology Product:

  • Amgen, Nplate(R) -- A thrombopoietin receptor agonist used in the treatment of thrombocytopenic purpura by increasing platelet counts without affecting the immune system.
  • GlaxoSmithKline, PROMACTA(R) -- Approved for the treatment of thrombocytopenia, the product increases platelet levels and does not inhibit normal antibody production.

Best Medical Technology:

  • Veridex, CellSearch(R) CTC Test -- The device is used to enumerate tumor cells in whole blood, making it the first of its kind that is capable of reliably isolating and identifying cells in patients with metastatic breast, colorectal or prostate cancer.

The Prix Galien Award (www.prix-galien-usa.com) recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines, and is considered the equivalent to the Nobel Prize. Prix Galien was first established in 1970 by French pharmacist Roland Mehl and was inaugurated in the United States in September 2007. The Prix Galien USA awards committee of 11 individuals includes seven Nobel Laureates, founders of major biotech companies and editors of world-renowned biology journals.

SOURCE Vanguard Communications


'/>"/>
SOURCE Vanguard Communications
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer
2. BIOCOMs 4th Annual DeviceFest Honors Companies
3. March of Dimes Honors Dr. Susan Carlson for Outstanding Work In Maternal-Fetal Nutrition
4. Michigan Life Science and Innovation Center Opens in Former Pfizer Facility
5. Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
6. MJFFs Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinsons Disease
7. Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative
8. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
9. NHS National Innovation Centre Cites VNUS Closure(R) Procedure as Select Innovative Technology
10. InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation
11. Wayne County Partners With TechTown to Launch Global Stem Cell Innovation and Commercialization Lab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology:
(Date:4/26/2017)... , ... April 26, 2017 ... ... provides an agile ecosystem and domain expertise for sponsors and CROs to ... and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... a breakthrough topical cream that’s the first in a new class of photodynamic ... the overall appearance of skin, visibly reduce outward signs of aging, and minimize ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
(Date:4/25/2017)... ... 2017 , ... A stressful work environment can hurt the physical and emotional ... performance in the workplace. The goal of Clearview Resolution Services has always been to ... Clearview Resolution Services will be shutting down the office early on Fridays. The Clearview ...
(Date:4/25/2017)... CO (PRWEB) , ... April 25, 2017 , ... ... and Liberty attempts to compare student test score performance for the 2015-16 school ... of the state’s voucher programs. Though it highlights important patterns in student test ...
Breaking Medicine News(10 mins):